TG Therapeutics to Host Conference Call on First Quarter 2021 Financial Results and Business Update
TG Therapeutics (NASDAQ: TGTX) has scheduled a conference call for May 10, 2021, at 8:30 AM ET to discuss its Q1 2021 financial results and provide a business outlook. The call will be led by Executive Chairman and CEO Michael S. Weiss. Participants can join the call by dialing the designated numbers or via a live webcast on the company's website. TG Therapeutics is focused on novel treatments for B-cell malignancies and autoimmune diseases, with several investigational medicines currently in development, including UKONIQ™, which has received accelerated FDA approval.
- TG Therapeutics has received accelerated FDA approval for UKONIQ™, expanding its treatment options for specific lymphomas.
- The company has a strong pipeline with five investigational medicines targeting B-cell malignancies and autoimmune diseases.
- The upcoming conference call will provide insights into the company's financial performance and strategic direction.
- None.
Conference call to be held Monday, May 10, 2021 at 8:30 AM ET
NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, May 10, 2021 at 8:30 AM ET to discuss results for the first quarter 2021 and provide a business outlook for 2021. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQ™ (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.
UKONIQ™ is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is the TG Therapeutics conference call scheduled?
What will be discussed during the TG Therapeutics conference call?
What is UKONIQ™ and its significance for TG Therapeutics?
How can investors participate in the TG Therapeutics conference call?
